Business
Eris Lifesciences Reports 11% YoY Growth In Domestic Formulations With Strong FY26 EBITDA Margin
By MILLENNIUM NEWSROOM Desk · May 24, 2026 04:53 PM
2 min read
Advertisement
Q4 & FY2026 Earnings Press Release
Eris delivers 11% yoy growth in Domestic Formulations with 37% EBITDA margin in FY26
Ahmedabad, May 20th, 2026: Eris Lifesciences Limited (“Eris Lifesciences” or the “Company”) (BSE: 540596; NSE: ERIS), a leading Indian branded formulations manufacturing company, today announced its earnings for the quarter and full year ended March 31, 2026.
Q4 and FY2026 Financial Performance Summary (Consolidated)
| Particulars (INR Cr) | Q4 FY26 | Q4 FY25 | YoY (%) | FY2026 | FY2025 | YoY (%) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 757 | 705 | 7% | 3,129 | 2,894 | 8% |
| Gross Profit | 571 | 535 | 7% | 2,334 | 2,180 | 7% |
| EBITDA EBITDA Margin (%) |
274 36.2% |
252 35.8% |
8% | 1,120 35.8% |
1,017 35.2% |
10% |
| Profit After Tax (PAT) PAT Margin (%) |
279 36.9% |
102 14.5% |
173% | 648 20.7% |
375 12.9% |
73% |
Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, said:
“Our Domestic Formulations business delivered a 11% revenue growth in FY26 with a 12% EBITDA growth and industry leading EBITDA margin of 37%. Our Insulins franchise has outpaced market growth by 5x in FY26 with a market share expansion from 12% to 16%. Our GLP brand Sundae has gotten off to a strong start, which reflects the present standing of the company in the Injectable Diabesity space. Sundae ranks #1 by volume (among injectables) in its very first month of launch.”
Q4 and FY2026 Key Financial Highlights
- DBF business revenue growth of 12% YoY in Q4 and 11% YoY in FY26 – EBITDA margin 37%
- Consolidated Revenue growth 7% YoY in Q4 and 8% YoY in FY26 – EBITDA margin 36%
- Consolidated Q4 PAT Rs. 279 Cr with a 174% growth, FY26 PAT Rs. 648 Cr, with a 73% growth
- Net debt as of March 31, 2026, stood at Rs. 2,255 Cr
Conference Call Details: Wednesday, May 20, 2026, at 4:30 PM IST
Management Representatives:
- Mr. Amit Bakshi – Chairman and Managing Director
- Mr. V. Krishnakumar – Chief Operating Officer & Executive Director
- Mr. Sachin Shah – Chief Financial Officer
- Ms. Kruti Raval – VP - M&A and Investor Relations
Joining Link: Click Here
Gallery
Photo Gallery
Advertisement